5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction.

5-alpha Reductase Inhibitors / administration & dosage Animals Antiparkinson Agents / administration & dosage Dutasteride / administration & dosage Dyskinesia, Drug-Induced / metabolism Finasteride / administration & dosage Levodopa / administration & dosage MAP Kinase Signaling System / drug effects Male Rats, Sprague-Dawley Receptors, Dopamine D1 / metabolism Receptors, Dopamine D3 / metabolism
5alpha-reductase 6-OHDA Dopamine Dutasteride Dyskinesia L-DOPA Neurosteroids Parkinson's disease

Journal

Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169

Informations de publication

Date de publication:
01 2019
Historique:
received: 01 06 2018
revised: 06 09 2018
accepted: 18 09 2018
pubmed: 28 9 2018
medline: 22 11 2019
entrez: 28 9 2018
Statut: ppublish

Résumé

Although 1-3,4-dihydroxyphenylalanine (L-DOPA) is the mainstay therapy for treating Parkinson's disease (PD), its long-term administration is accompanied by the development of motor complications, particularly L-DOPA induced dyskinesia (LID), that dramatically affects patients' quality of life. LID has consistently been related to an excessive dopamine receptor transmission, particularly at the down-stream signaling of the striatal D

Identifiants

DOI: 10.1016/j.nbd.2018.09.018 PMID: 30261284
pubmed: 30261284
pii: S0969-9961(18)30605-3
doi: 10.1016/j.nbd.2018.09.018
pii:
doi:

Substances chimiques

5-alpha Reductase Inhibitors 0
Antiparkinson Agents 0
Receptors, Dopamine D1 0
Receptors, Dopamine D3 0
Levodopa 46627O600J
Finasteride 57GNO57U7G
Dutasteride O0J6XJN02I

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

120-130

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Silvia Fanni (S)

Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria SP 8, Monserrato 09042, Italy.

Simona Scheggi (S)

Department of Molecular and Developmental Medicine, University of Siena, Via Aldo Moro 4, 53100 Siena, Italy.

Francesca Rossi (F)

Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria SP 8, Monserrato 09042, Italy.

Elisabetta Tronci (E)

Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria SP 8, Monserrato 09042, Italy.

Francesco Traccis (F)

Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria SP 8, Monserrato 09042, Italy.

Roberto Stancampiano (R)

Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria SP 8, Monserrato 09042, Italy.

Maria Graziella De Montis (MG)

Department of Molecular and Developmental Medicine, University of Siena, Via Aldo Moro 4, 53100 Siena, Italy.

Paola Devoto (P)

Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria SP 8, Monserrato 09042, Italy.

Carla Gambarana (C)

Department of Molecular and Developmental Medicine, University of Siena, Via Aldo Moro 4, 53100 Siena, Italy.

Marco Bortolato (M)

Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, 30 S 2000 E, Salt Lake City, UT 84112, USA.

Roberto Frau (R)

Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria SP 8, Monserrato 09042, Italy; Tourette Syndrome Center, University of Cagliari, Cittadella Universitaria SP 8, Monserrato 09042, Italy; Sleep Medicine Center, University of Cagliari, Cittadella Universitaria SP 8, Monserrato 09042, Italy; National Institute of Neuroscience (INN), University of Cagliari, Monserrato, CA, Italy. Electronic address: roberto.frau@unica.it.

Manolo Carta (M)

Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria SP 8, Monserrato 09042, Italy. Electronic address: manolocarta@unica.it.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Antihormones › Inhibiteurs de la synthèse des stéroïdes › Inhibiteurs de la 5-alpha réductase › 5alpha-reductase inhibitors dampen...
questionsmedicales.fr › Eucaryotes › Animaux › 5alpha-reductase inhibitors dampen...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Antidyskinésiques › Antiparkinsoniens › 5alpha-reductase inhibitors dampen...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Stéroïdes hétérocycliques › Azastéroïde › Dutastéride › 5alpha-reductase inhibitors dampen...
questionsmedicales.fr › Troubles dus à des produits chimiques › Intoxication › Syndromes neurotoxiques › Dyskinésie due aux médicaments › 5alpha-reductase inhibitors dampen...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Stéroïdes hétérocycliques › Azastéroïde › Finastéride › 5alpha-reductase inhibitors dampen...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés cycliques › Acides aminés aromatiques › Tyrosine › Dopa › Lévodopa › 5alpha-reductase inhibitors dampen...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Système de signalisation des MAP kinases › 5alpha-reductase inhibitors dampen...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Rat Sprague-Dawley › 5alpha-reductase inhibitors dampen...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs catécholaminergiques › Récepteurs dopaminergiques › Récepteur dopamine D1 › 5alpha-reductase inhibitors dampen...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs catécholaminergiques › Récepteurs dopaminergiques › Récepteur D2 de la dopamine › Récepteur D3 de la dopamine › 5alpha-reductase inhibitors dampen...